Skip to main content
Top
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Inhibitory effect of a novel peptide, H-RN, on keratitis induced by LPS or poly(I:C) in vitro and in vivo via suppressing NF-κB and MAPK activation

Authors: Shaopin Zhu, Xun Xu, Lili Wang, Li Su, Qing Gu, Fang Wei, Kun Liu

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

Keratitis is a common cause of blindness. Current anti-inflammatory drugs used in keratitis have profound side effects. Small peptides derived from endogenous proteins potentially display both desired efficiency and safety. We identified an 11-amino-acid peptide, H-RN, from hepatocyte growth factor (HGF), an endogenous protein with anti-inflammatory properties. We evaluated the effects of H-RN in keratitis in vitro and in vivo.

Methods

In vitro, corneal fibroblasts were stimulated with LPS or poly(I:C), surrogates for bacteria and viruses. Inflammatory cytokines, intercellular cell adhesion molecule-1 (ICAM-1), translocation of NF-κB p65, activation of IκBα, NF-κB, and MAPKs were detected. In vivo, keratitis in rats was induced by LPS. Clinical, histological observation, and quantification of cytokines in the cornea were conducted. H-RN safety was measured by cell viability, clinical, histological, and microstructural observations.

Results

H-RN inhibited IL-6, monocyte chemotactic protein-1(MCP-1), Interferon- γ(IFN-γ), and ICAM-1 expression triggered by LPS or poly(I:C), alleviated the clinical manifestation and reduced the clinical score in keratitis in vivo. The histological disorder and proinflammatory cytokines of the cornea were also reduced. The translocation of NF-κB and phosphorylation of IκBα, NF-κB, p38, JNK, and ERK were significantly inhibited by H-RN. No sign of toxicity was observed.

Conclusions

H-RN effectively attenuated keratitis in vivo and in vitro induced by LPS or poly(I:C) through blocking NF-κB and MAPK signaling pathways. It may be a promising and safe agent in treating keratitis.
Literature
1.
go back to reference Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79:214–21.PubMedPubMedCentral Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79:214–21.PubMedPubMedCentral
2.
go back to reference Carlson EC, Drazba J, Yang X, Perez VL. Visualization and characterization of inflammatory cell recruitment and migration through the corneal stroma in endotoxin-induced keratitis. Invest Ophthalmol Vis Sci. 2006;47:241–8.CrossRefPubMed Carlson EC, Drazba J, Yang X, Perez VL. Visualization and characterization of inflammatory cell recruitment and migration through the corneal stroma in endotoxin-induced keratitis. Invest Ophthalmol Vis Sci. 2006;47:241–8.CrossRefPubMed
3.
go back to reference Kimura K, Orita T, Nomi N, Fujitsu Y, Nishida T, Sonoda KH. Identification of common secreted factors in human corneal fibroblasts exposed to LPS, poly(I:C), or zymosan. Exp Eye Res. 2012;96:157–62.CrossRefPubMed Kimura K, Orita T, Nomi N, Fujitsu Y, Nishida T, Sonoda KH. Identification of common secreted factors in human corneal fibroblasts exposed to LPS, poly(I:C), or zymosan. Exp Eye Res. 2012;96:157–62.CrossRefPubMed
4.
go back to reference Fukuda K, Fujitsu Y, Kumagai N, Nishida T. Characterization of the interleukin-4 receptor complex in human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2002;43:183–8.PubMed Fukuda K, Fujitsu Y, Kumagai N, Nishida T. Characterization of the interleukin-4 receptor complex in human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2002;43:183–8.PubMed
5.
go back to reference Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131–5.CrossRefPubMed Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131–5.CrossRefPubMed
6.
go back to reference Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des. 2007;13:2074–86.CrossRefPubMed Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des. 2007;13:2074–86.CrossRefPubMed
7.
go back to reference Sheets AR, Massey CJ, Cronk SM, Iafrati MD, Herman IM. Matrix- and plasma-derived peptides promote tissue-specific injury responses and wound healing in diabetic swine. J Transl Med. 2016;14:197.CrossRefPubMedPubMedCentral Sheets AR, Massey CJ, Cronk SM, Iafrati MD, Herman IM. Matrix- and plasma-derived peptides promote tissue-specific injury responses and wound healing in diabetic swine. J Transl Med. 2016;14:197.CrossRefPubMedPubMedCentral
8.
go back to reference Watanabe M, Ebina M, Orson FM, Nakamura A, Kubota K, Koinuma D, et al. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther. 2005;12:58–67.CrossRefPubMed Watanabe M, Ebina M, Orson FM, Nakamura A, Kubota K, Koinuma D, et al. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther. 2005;12:58–67.CrossRefPubMed
9.
go back to reference Okunishi K, Dohi M, Fujio K, Nakagome K, Tabata Y, Okasora T, et al. Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. J Immunol. 2007;179:5504–13.CrossRefPubMed Okunishi K, Dohi M, Fujio K, Nakagome K, Tabata Y, Okasora T, et al. Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. J Immunol. 2007;179:5504–13.CrossRefPubMed
10.
go back to reference Benkhoucha M, Molnarfi N, Dunand-Sauthier I, Merkler D, Schneiter G, Bruscoli S, et al. Hepatocyte growth factor limits autoimmune neuroinflammation via glucocorticoid-induced leucine zipper expression in dendritic cells. J Immunol. 2014;193:2743–52.CrossRefPubMed Benkhoucha M, Molnarfi N, Dunand-Sauthier I, Merkler D, Schneiter G, Bruscoli S, et al. Hepatocyte growth factor limits autoimmune neuroinflammation via glucocorticoid-induced leucine zipper expression in dendritic cells. J Immunol. 2014;193:2743–52.CrossRefPubMed
11.
go back to reference Touchard E, Omri S, Naud MC, Berdugo M, Deloche C, Abadie C, et al. A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2010;51:4683–93.CrossRefPubMed Touchard E, Omri S, Naud MC, Berdugo M, Deloche C, Abadie C, et al. A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2010;51:4683–93.CrossRefPubMed
12.
go back to reference Hernandez-Ledesma B, Hsieh CC, de Lumen BO. Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem Biophys Res Commun. 2009;390:803–8.CrossRefPubMed Hernandez-Ledesma B, Hsieh CC, de Lumen BO. Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem Biophys Res Commun. 2009;390:803–8.CrossRefPubMed
13.
go back to reference Wang L, Xu Y, Yu Q, Sun Q, Gu Q, Xu X. H-RN, a novel antiangiogenic peptide derived from hepatocyte growth factor inhibits inflammation in vitro and in vivo through PI3 K/AKT/IKK/NF-kappaB signal pathway. Biochem Pharmacol. 2014;89:255–65.CrossRefPubMed Wang L, Xu Y, Yu Q, Sun Q, Gu Q, Xu X. H-RN, a novel antiangiogenic peptide derived from hepatocyte growth factor inhibits inflammation in vitro and in vivo through PI3 K/AKT/IKK/NF-kappaB signal pathway. Biochem Pharmacol. 2014;89:255–65.CrossRefPubMed
14.
go back to reference Xu Y, Zhao H, Zheng Y, Gu Q, Ma J, Xu X. A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Mol Vis. 2010;16:1982–95.PubMedPubMedCentral Xu Y, Zhao H, Zheng Y, Gu Q, Ma J, Xu X. A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Mol Vis. 2010;16:1982–95.PubMedPubMedCentral
15.
go back to reference Yang X, Jin H, Liu K, Gu Q, Xu X. A novel peptide derived from human pancreatitis-associated protein inhibits inflammation in vivo and in vitro and blocks NF-kappa B signaling pathway. PLoS ONE. 2011;6:e29155.CrossRefPubMedPubMedCentral Yang X, Jin H, Liu K, Gu Q, Xu X. A novel peptide derived from human pancreatitis-associated protein inhibits inflammation in vivo and in vitro and blocks NF-kappa B signaling pathway. PLoS ONE. 2011;6:e29155.CrossRefPubMedPubMedCentral
16.
go back to reference Anand BS, Hill JM, Dey S, Maruyama K, Bhattacharjee PS, Myles ME, et al. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol Vis Sci. 2003;44:2529–34.CrossRefPubMed Anand BS, Hill JM, Dey S, Maruyama K, Bhattacharjee PS, Myles ME, et al. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol Vis Sci. 2003;44:2529–34.CrossRefPubMed
17.
go back to reference Khatri S, Lass JH, Heinzel FP, Petroll WM, Gomez J, Diaconu E, et al. Regulation of endotoxin-induced keratitis by PECAM-1, MIP-2, and toll-like receptor 4. Invest Ophthalmol Vis Sci. 2002;43:2278–84.PubMed Khatri S, Lass JH, Heinzel FP, Petroll WM, Gomez J, Diaconu E, et al. Regulation of endotoxin-induced keratitis by PECAM-1, MIP-2, and toll-like receptor 4. Invest Ophthalmol Vis Sci. 2002;43:2278–84.PubMed
18.
19.
go back to reference Adebayo D, Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006;82:186–91.CrossRefPubMedPubMedCentral Adebayo D, Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006;82:186–91.CrossRefPubMedPubMedCentral
20.
go back to reference Tempest-Roe S, Joshi L, Dick AD, Taylor SR. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol. 2013;13:39.CrossRefPubMedPubMedCentral Tempest-Roe S, Joshi L, Dick AD, Taylor SR. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol. 2013;13:39.CrossRefPubMedPubMedCentral
22.
go back to reference Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2014;47:136–47.CrossRefPubMed Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2014;47:136–47.CrossRefPubMed
23.
go back to reference Ueta M, Kinoshita S. Ocular surface inflammation mediated by innate immunity. Eye Contact Lens. 2010;36:269–81.CrossRefPubMed Ueta M, Kinoshita S. Ocular surface inflammation mediated by innate immunity. Eye Contact Lens. 2010;36:269–81.CrossRefPubMed
24.
go back to reference Pandey RK, Yu FS, Kumar A. Targeting toll-like receptor signaling as a novel approach to prevent ocular infectious diseases. Indian J Med Res. 2013;138:609–19.PubMedPubMedCentral Pandey RK, Yu FS, Kumar A. Targeting toll-like receptor signaling as a novel approach to prevent ocular infectious diseases. Indian J Med Res. 2013;138:609–19.PubMedPubMedCentral
25.
go back to reference Liu Y, Kimura K, Yanai R, Chikama T, Nishida T. Cytokine, chemokine, and adhesion molecule expression mediated by MAPKs in human corneal fibroblasts exposed to poly(I:C). Invest Ophthalmol Vis Sci. 2008;49:3336–44.CrossRefPubMed Liu Y, Kimura K, Yanai R, Chikama T, Nishida T. Cytokine, chemokine, and adhesion molecule expression mediated by MAPKs in human corneal fibroblasts exposed to poly(I:C). Invest Ophthalmol Vis Sci. 2008;49:3336–44.CrossRefPubMed
26.
go back to reference Orita T, Kimura K, Nishida T, Sonoda KH. Cytokine and chemokine secretion induced by poly(I:C) through NF-kappaB and phosphoinositide 3-kinase signaling pathways in human corneal fibroblasts. Curr Eye Res. 2013;38:53–9.CrossRefPubMed Orita T, Kimura K, Nishida T, Sonoda KH. Cytokine and chemokine secretion induced by poly(I:C) through NF-kappaB and phosphoinositide 3-kinase signaling pathways in human corneal fibroblasts. Curr Eye Res. 2013;38:53–9.CrossRefPubMed
27.
go back to reference Sun Y, Su L, Wang Z, Xu Y, Xu X. H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle. BMC Cell Biol. 2013;14:8.CrossRefPubMedPubMedCentral Sun Y, Su L, Wang Z, Xu Y, Xu X. H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle. BMC Cell Biol. 2013;14:8.CrossRefPubMedPubMedCentral
28.
go back to reference Kimura K, Orita T, Kondo Y, Zhou H, Nishida T. Upregulation of matrix metalloproteinase expression by poly(I:C) in corneal fibroblasts: role of NF-kappaB and interleukin-1ss. Invest Ophthalmol Vis Sci. 2010;51:5012–8.CrossRefPubMed Kimura K, Orita T, Kondo Y, Zhou H, Nishida T. Upregulation of matrix metalloproteinase expression by poly(I:C) in corneal fibroblasts: role of NF-kappaB and interleukin-1ss. Invest Ophthalmol Vis Sci. 2010;51:5012–8.CrossRefPubMed
29.
go back to reference Fukuda K, Kumagai N, Yamamoto K, Fujitsu Y, Chikamoto N, Nishida T. Potentiation of lipopolysaccharide-induced chemokine and adhesion molecule expression in corneal fibroblasts by soluble CD14 or LPS-binding protein. Invest Ophthalmol Vis Sci. 2005;46:3095–101.CrossRefPubMed Fukuda K, Kumagai N, Yamamoto K, Fujitsu Y, Chikamoto N, Nishida T. Potentiation of lipopolysaccharide-induced chemokine and adhesion molecule expression in corneal fibroblasts by soluble CD14 or LPS-binding protein. Invest Ophthalmol Vis Sci. 2005;46:3095–101.CrossRefPubMed
31.
go back to reference Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009;18:1893–905.CrossRefPubMed Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009;18:1893–905.CrossRefPubMed
32.
go back to reference Cheng L, Hostetler K, Valiaeva N, Tammewar A, Freeman WR, Beadle J, et al. Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci. 2010;51:474–81.CrossRefPubMedPubMedCentral Cheng L, Hostetler K, Valiaeva N, Tammewar A, Freeman WR, Beadle J, et al. Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci. 2010;51:474–81.CrossRefPubMedPubMedCentral
33.
go back to reference Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30:351–67.CrossRefPubMed Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30:351–67.CrossRefPubMed
Metadata
Title
Inhibitory effect of a novel peptide, H-RN, on keratitis induced by LPS or poly(I:C) in vitro and in vivo via suppressing NF-κB and MAPK activation
Authors
Shaopin Zhu
Xun Xu
Lili Wang
Li Su
Qing Gu
Fang Wei
Kun Liu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1121-z

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.